Sheng Y, Kandiah D A, Krilis S A
Department of Immunology, Allergy and Infectious Disease, University of New South Wales, The St George Hospital, Kogarah, Australia.
Lupus. 1998;7 Suppl 2:S5-9. doi: 10.1177/096120339800700202.
It has become clear that beta2-glycoprotein I (beta2GPI) is the most common and best-characterised antigenic target for 'antiphospholipid' (aPL) autoantibodies. These antibodies preferentially bind beta2GPI that has been immobilised on anionic phospholipid membranes or certain synthetic surfaces. These surfaces appear to act by increasing antigen density to allow binding of intrinsically low-affinity anti-beta2GPI autoantibodies. Binding of beta2GPI in fluid phase is weak and requires high concentrations of beta2GPI. Our understanding of the pathophysiology of the 'Antiphospholipid' Syndrome (APS) has increased exponentially with the number of studies into the interactions of aPL antibodies and beta2GPI.
目前已经明确，β2糖蛋白I（β2GPI）是“抗磷脂”（aPL）自身抗体最常见且特征最明确的抗原靶点。这些抗体优先结合固定在阴离子磷脂膜或某些合成表面上的β2GPI。这些表面似乎通过增加抗原密度来发挥作用，以使内在低亲和力的抗β2GPI自身抗体能够结合。β2GPI在液相中的结合较弱，需要高浓度的β2GPI。随着对aPL抗体与β2GPI相互作用研究数量的增加，我们对“抗磷脂”综合征（APS）病理生理学的理解呈指数级增长。
